Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/9/2017
SIETES contiene 92006 citas

 
 
 1 a 20 de 1769 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Dimmitt S, Stampfer H, Martin JH. When less is more – Efficacy with less toxicity at the ED50. Br J Clin Pharmacol 2017;83:1365-8. [Ref.ID 101984]
2. Cita con resumen
Shin J-Y, Eberg M, Enrst P, Filion KB. Statin potency and the risk of hospitalization for community-acquired pneumonia. Br J Clin Pharmacol 2017;83:1319-27. [Ref.ID 101943]
3. Cita con resumen
Makris UE, Alvarez CA, Wei W, Mortensen EM, Mansi IA. Association of statin use with risk of back disorder diagnoses. JAMA Intern Med 2017;177:julio. [Ref.ID 101673]
4. Cita con resumen
Pedro-Botet J, Rubiés-Prat J. Statin-associated muscle symptoms: beware of the nocebo effect. Lancet 2017;389:2445-6. [Ref.ID 101655]
5.Tiene citas relacionadas Cita con resumen
Schoenfeld AJ, Redberg RF. The value of using registries to evaluate randomized clinical trial study populations. JAMA Intern Med 2017;177:889. [Ref.ID 101623]
6.Tiene citas relacionadas Cita con resumen
Maddox TM, Tang F, Downs JR, Masoudi FA, Virani SS, Daugherty SL, Rumsfeld JS. Applicability of the IMPROVE-IT trial to current patients with acute coronary syndrome: an NCDR research to practice project. JAMA Intern Med 2017;177:887-9. [Ref.ID 101622]
7.Tiene citas relacionadas Cita con resumen
Curfman G. Risks of statin therapy in older adults. JAMA Intern Med 2017;177:966. [Ref.ID 101591]
8.Tiene citas relacionadas Cita con resumen
Han BH, Sutin D, Williamson JD, Davis BR, Piller LB, Pervin H, Pressel SL, Blaum CS, for the ALLHAT Collaborative Research Group. Effect of statin treatment vs usual care on primary cardiovascular prevention among older adults. The ALLHAT-LLT randomized clinical trial. JAMA Intern Med 2017;177:955-65. [Ref.ID 101590]
9. Cita con resumen
Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR, FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376:1713-22. [Ref.ID 101586]
11. Cita con resumen
Greenway T, Ross JS. US drug marketing: how does promotion correspond with health value?. BMJ 2017;357:j1855. [Ref.ID 101571]
12. Cita con resumen
Larkin I, Ang D, Steinhart J, Chao M, Patterson M, Sah S, Wu T, Schoen-baum M, Hutchins D, Brennan T, Loewen-stein G. Association between academic medical center pharmaceutical detailing policies and physician prescribing. JAMA 2017;317:1785-95. [Ref.ID 101559]
13. Cita con resumen
Chobanian AV. Hypertension in 2017- What is the right target?. JAMA 2017;317:579-80. [Ref.ID 101415]
14. Cita con resumen
McGettigan P, Ferner RE. PCSK9 inhibitors for hypercholesterolaemia. BMJ 2017;356:j188. [Ref.ID 101397]
15. Cita con resumen
Khan AR, Bavishi C, Riaz H, Farid TA, Khan S, Atlas M, Hirsch G, Ikram S, Bolli R. Increased risk of adverse neurocognitive outcomes with proprotein convertase subtilisin-kexin type 9 inhibitors. Circulation: Cardiovascular Quality and Outcomes 2017;10:e003153. [Ref.ID 101377]
16. Cita con resumen
Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJ, Koenig W, Somaratne R, Kassahun H, Yang J, Wasserman SM, Scott R, Unqi I, Podolec J, Ophuis AO, Cornel JH, Borgman M, Brennan DM, Nissen SE. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAVOV randomized clinical trial. JAMA 2016;316:2373-84. [Ref.ID 101030]
18.Enlace a cita originalTiene citas relacionadas
19.Enlace a cita originalTiene citas relacionadas
Redberg RF, Katz MH. Statins for primary prevention: the debate is intense, but the data are weak. JAMA 2016;316:1979-81. [Ref.ID 100987]
20.Enlace a cita originalTiene citas relacionadas
Greenland P, Bonow RO. Interpretation and use of another statin guideline. JAMA 2016;316:1977-9. [Ref.ID 100986]
Seleccionar todas
 
 1 a 20 de 1769 siguiente >>